Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 1/27/16  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Peter R. Mueller

Wrong Dr. Peter R. Mueller?

Chief Scientific Officer

Pronutria Biosciences , Inc.
Phone: (617) ***-****  HQ Phone
Email: p***@***.com
Pronutria Inc
840 Memorial Drive Third Floor
Cambridge , Massachusetts 02139
United States

Company Description: Pronutria created a revolutionary platform for identifying protein nutrients from within the human diet that have potent pharmacological effects, opening a vast...   more
Background

Employment History

Board Memberships and Affiliations

Education

  • PhD , Chemistry
    Albert Einstein University of Ulm , Germany
  • undergraduate degree
    Albert Einstein University of Ulm , Germany
  • Ph.D. , Chemistry
    Albert Einstein University of Ulm , Germany
143 Total References
Web References
USA India Chamber of commerce - Delivering Affordable Innovation through Global Partnerships
www.usaindiachamber.org, 27 Jan 2016 [cached]
Dr. Peter Mueller, President of R&D and Chief Scientific Officer, Pronutria BioSciences
...
Peter Mueller,PhD President R&D and CSO Pronutria Biosciences
...
Peter Mueller, PhD; President R&D and Chief Scientific Officer, Pronutria BioSciences
USA India Chamber of commerce - Delivering Affordable Innovation through Global Partnerships
www.usaindiachamber.org, 27 Jan 2016 [cached]
Dr. Peter Mueller President R&D and CSO Pronutria Biosciences
USA India Chamber of commerce - BioTech, Pharmaceuticals, Healthcare Council
www.usaindiachamber.org, 27 Jan 2016 [cached]
Peter Mueller, Ph.D. Chief Scientific Officer and Executive Vice President
Board of Directors | Inhibikase Therapeutics, Inc.
www.inhibikase.com, 28 Jan 2016 [cached]
Peter Mueller, PhD.
Dr. Mueller joined Vertex in July 2003. As Executive Vice President Global Research and Development & Chief Scientific Officer, he provides strategic oversight for Vertex's worldwide drug discovery research programs, Pharmaceutical Development, Quality Assurance and Control, Pharmaceutical Operations as well as Clinical and Non-Clinical Development, Regulatory, Patient Safety and Medical Affairs. Key areas of Vertex' R&D are Hepatitis C, Cystic Fibrosis, IMID, Cancer, and Neurological Diseases which led in 2011 to the successful approval and launch of INCIVEK (HepC), a NDA/MAA submission for KALYDECO (CF) with the first approval in the US in January 2012 and several proof of clinical concept candidates in various disease areas. Prior to coming to Vertex, Dr. Mueller served as Senior Vice President, Research and Development, for Boehringer Ingelheim Pharmaceuticals, Inc. where he was responsible for the development of all drug candidates of the company's worldwide portfolio in North and South America, Canada and Japan, beginning in 1997. He also led research programs in the areas of immunology, inflammation, cardiovascular disease and gene therapy on a global basis. During his time with Boehringer Ingelheim, Dr. Mueller oversaw the discovery of numerous development candidates, held several positions in basic research, medicinal chemistry and management in different centers of BI worldwide.
Dr. Mueller received both an undergraduate degree and a Ph.D. in Chemistry at the Albert Einstein University of Ulm, Germany, where he also holds a Professorship in Theoretical Organic Chemistry. He completed fellowships in Quantum Pharmacology at Oxford University and in Biophysics at Rochester University.
Vertex Announces Retirement of ...
investors.vrtx.com, 31 Oct 2014 [cached]
Vertex Announces Retirement of Peter Mueller, Ph.D. | Read more | « Previous Release Vertex Announces Retirement of Peter Mueller, Ph.D. (NASDAQ:VRTX)
...
Vertex Announces Retirement of Peter Mueller, Ph.D.
BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Peter Mueller
...
Dr. Mueller's retirement will be effective October 31, 2014 , following a planned transition period. Dr. Mueller joined Vertex in 2003 as Chief Scientific Officer and Senior Vice President, Drug Discovery and Innovation.
"Peter is a visionary who embodied Vertex's fearless pursuit of transformational medicines," said Jeffrey Leiden , M.D., Ph.D., Chairman, President and Chief Executive Officer of Vertex. "I thank Peter for his leadership, innovation and dedication to Vertex over the past decade."
...
to oversee the company's drug discovery efforts following Dr. Mueller's retirement.
Other People with the name "Mueller":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304